Bavarian Nordic has entered into an agreement to acquire Emergent BioSolutions' travel health business for a total value of up to $380 million.
The sale includes two marketed travel vaccines, as well as a phase 3 vaccine candidate for the prevention of Chikungunya virus.
Bavarian Nordic will also acquire Emergent’s manufacturing site in Bern, Switzerland, and development facilities in San Diego, California. Approximately 280 current Emergent employees are expected to join Bavarian Nordic as part of the transaction.
The Denmark-based drugmaker, looking to establish itself as a global leader in travel vaccines, will make an upfront payment of $270 million and up to $110 million in future conditional milestone payments.
The sale of its travel health business builds on Emergent’s previously announced strategic prioritization of its medical countermeasure products, including its smallpox vaccines, several anthrax products, and opioid overdose reversal medicine Narcan, as well as its contract development and manufacturing services businesses.
